GlycoVaxyn AG Raises CHF 25 Million in Financing Led by Edmond de Rothschild Investmen... ( SCHLIEREN Switzerland March 5 /- ...)

GlycoVaxyn AG Raises CHF 25 Million in Financing Led by Edmond de Rothschild Investment Partners

Date:3/5/2009

SCHLIEREN, Switzerland, March 5 /PRNewswire/ --

- Proceeds to Facilitate Clinical Development of Lead Conjugate Vaccine

GlycoVaxyn, a pioneer in the development of innovative conjugated vaccines, today announced the successful closing of a CHF25 million (ca. US$22 million, EUR17 million) Series B financing. The round was led by Edmond de Rothschild Investment Partners. Existing investors, Index Ventures and Sofinnova Partners, expressed their commitment to the future of the company through significant participation in this round.

Conjugated vaccines provide protection against a growing range of life-threatening bacterial infections. GlycoVaxyn has developed a proprietary technology that allows the engineering of a new type of conjugate vaccine, glycoconjugates. This innovation will enable GlycoVaxyn to address significant unmet medical needs in both industrialized and emerging countries.

The new funds will be used to advance the company's lead vaccine candidate for intestinal infections (Shigellosis), which can cause a major public health issue, into clinical development within the next 12 months. GlycoVaxyn also aims to reach key milestones in its Staphylococcus aureus, Group B meningococcal and Group A Streptococcus conjugate vaccine programs.

In conjunction with the financing, Gilles Nobecourt, Partner at Edmond de Rothschild Investment Partners, has joined GlycoVaxyn's Board of Directors. Of the transaction, he said: "After reviewing several investment opportunities in the field, Edmond de Rothschild Investment Partners has come to the conclusion that GlycoVaxyn has currently one of the most powerful new technology platforms, which has delivered several very promising vaccine candidates. The Company now has sufficient funds to move to the next, clinical stage in its development. I look forward to contribute to the future growth of this company as a Board member.
'/>"/>

0

GOOD

Page: 1 2
Related biology technology :

1. Eiger BioPharmaceuticals Raises $7.1 Million A Round
2. NanoBio Corporation Raises $12 Million in Series B Financing
3. Divergence Raises $11.8 Million in Series C Financing
4. Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009.
5. AMERIGROUP Praises Expansion of State Childrens Health Insurance Program (SCHIP)
6. JMAR Technologies Raises Awareness of BioSentry -- A High Tech Counter to Bioterrorism
7. Anacor Raises $50 Million in Equity Financing
8. MichBio Expo Draws Nearly 500 Professionals; Career Day Raises Profile
9. Sensorin Raises Equity Financing to Launch Novel Industrial Sensing Venture
10. Simbionix Raises Largest Amount in Companys History in Venture Capital to Accelerate Growth
11. Vista Partners Updates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx), Raises Target Price to AU$1.65

Post Your Comments:

GlycoVaxyn AG Raises CHF 25 Million in Financing Led by Edmond de Rothschild Investmen...( SCHLIEREN Switzerland March 5 /- ...)